Friday, 16 October 2026European Markets

PROACTIS SA Stock Is 21% Up In The Last 10 Sessions

Loading stream...

shares of proactis sa, a provider of software technology listed on france's cac 40 index, recently experienced a surprising 21.95% increase over the course of 10 sessions. moving from eur0.08 to eur0.10, this impressive ascent came even after the stock endured five consecutive days of losses. notably, this performance stands out as it directly follows five consecutive losses on previous instances.

surge amid declining performance

despite the general declining performance of the cac 40 index, which has dipped by 0.72% following two subsequent sessions of losses to reach eur7,260.53, shares of proactis sa have experienced a remarkable upward trend.

company overview

based in suresnes, france, proactis sa currently trades 35.14% below its 52-week high of eur0.15. the company is well-known within its industry for harnessing integrated software solutions to monitor business expenditure through proactis euro hedgeco limited. this subsidiary also provides a range of services including invoice capture and supplier onboarding.

earnings and profitability

at present, proactis sa's earnings per share (eps) for the preceding twelve months stand at eur-0.01, demonstrating that the company is not generating profits in spite of the increase in its stock price. the company's return on equity also validates this negative financial situation, currently measuring at -3.88%.

trading volume

proactis sa shares recently exchanged hands at an exceptionally low volume. only 31 shares were traded in contrast to the average daily volume of 7,207. this low trading volume could potentially amplify the stock's price volatility in the near future.

potential instability

although proactis sa's recent stock performance has offered some glimmers of hope, the company's negative profitability measures and low trading volume suggest possible instability. it is recommended that investors approach with caution and continuously evaluate proactis' financial performance and market trends before investing based on these outcomes.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com